Amicus Therapeutics
As of the edition of 20 October 2026, Amicus Therapeutics runs 26 drugs, 14 of them marketed; it is on route A at 3 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 13 company names in this family.
- AMICUS THERAPEUTICS, INC.: acquired in 2026; successor BIOMARIN PHARMACEUTICAL INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Active | 3 |
| Went quiet | 2 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 26 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Prednisolone | none listed | 6 |
| Sapropterin | none listed | 1 |
| Miglustat | none listed | 2 |
| Migalastat | Ends 2039 (patent) | 1 |
| Laronidase | Ended 2015 (computed from the first US licence) | 0 |
| Vosoritide | Ends 2035 (patent) | 1 |
| Elosulfase alfa | Ended 2026 (computed from the first US licence) | 0 |
| Pegvaliase | Ends 2030 (computed from the first US licence) | 0 |
| Cipaglucosidase alfa | Ends 2035 (computed from the first US licence) | 1 |
| Valoctocogene roxaparvovec | Ends 2035 (computed from the first US licence) | 0 |
| Prednisolone phosphoric acid | none listed | 2 |
| Vestronidase alfa | Ends 2029 (computed from the first US licence) | 0 |
| Cerliponase alfa | Ends 2031 (orphan exclusivity) | 0 |
| Galsulfase | Ended 2017 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 3 targets, route B at 5 targets.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where Amicus Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 89 trials led
- Nutrition and metabolism: 65 trials led
- Nervous system: 61 trials led